Diabetes Metab J.  2024 May;48(3):387-389. 10.4093/dmj.2024.0168.

Does Rosuvastatin/Ezetimibe Combination Therapy Offer Potential Benefits for Glucose Metabolism beyond Lipid-Lowering Efficacy in T2DM?

• Park IR
• Moon JS

• KMID: 2555770
• DOI: http://doi.org/10.4093/dmj.2024.0168

Reference

1. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012; 380:565–71.

2. Thakker D, Nair S, Pagada A, Jamdade V, Malik A. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf. 2016; 25:1131–49.

3. Kim YS, Han YE, Choi EA, You NY, Lee JW, You HS, et al. Statin use increased new-onset diabetes in hypercholesterolemic individuals: data from the Korean National Health Insurance Service-National Health Screening Cohort database (NHIS-HEALS). Prim Care Diabetes. 2020; 14:246–53.

4. Galicia-Garcia U, Jebari S, Larrea-Sebal A, Uribe KB, Siddiqi H, Ostolaza H, et al. Statin treatment-induced development of type 2 diabetes: from clinical evidence to mechanistic insights. Int J Mol Sci. 2020; 21:4725.

5. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002; 90:1084–91.

6. Hong N, Lee YH, Tsujita K, Gonzalez JA, Kramer CM, Kovarnik T, et al. Comparison of the effects of ezetimibe-statin combination therapy on major adverse cardiovascular events in patients with and without diabetes: a meta-analysis. Endocrinol Metab (Seoul). 2018; 33:219–27.

7. Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022; 400:380–90.

8. Moon JS, Park IR, Kim SS, Kim HS, Kim NH, Kim SG, et al. The efficacy and safety of moderate-intensity rosuvastatin with ezetimibe versus high-intensity rosuvastatin in high atherosclerotic cardiovascular disease risk patients with type 2 diabetes mellitus: a randomized, multicenter, open, parallel, phase 4 study. Diabetes Metab J. 2023; 47:818–25.

9. Han JH, Joung KH, Lee JC, Kim OS, Choung S, Kim JM, et al. Comparative efficacy of rosuvastatin monotherapy and rosuvastatin/ezetimibe combination therapy on insulin sensitivity and vascular inflammatory response in patients with type 2 diabetes mellitus. Diabetes Metab J. 2024; 48:112–21.